Collegium Pharmaceutical

Update in progress

COLL (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Collegium Pharmaceutical, Inc. is a specialty pharma company focused on developing and commercializing medicines for pain management. Its portfolio includes Jornay PM (methylphenidate HCl) for ADHD; Belbuca (buprenorphine) for chronic severe pain; Xtampza ER (abuse-deterrent oxycodone) for severe pain; Nucynta ER/IR (tapentadol) for acute and persistent pain; and Symproic (naldemedine) for opioid-induced constipation in adults with chronic non-cancer pain. Headquartered in Stoughton, MA, the company was founded in 2002 and renamed Collegium Pharmaceutical, Inc. in 2003.

Company score

Sentiment: 0.37; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationUnited States
CEOMr. Vikram Karnani
Founded2002
Employees423
Websitewww.collegiumpharma.com

Identifiers

ISINUS19459J1043
FIGIBBG000N7LPW4
LEI54930049FXZMTLW8D496
CUSIP19459J104
CIK0001267565